Company Name eFFECTOR Therapeutics
Mailing Address 11180 Roselle Street San Diego, CA 92121 USA
Company Description eFFECTOR Therapeutics is pioneering a new class of small molecule drugs that act by selectively regulating translation, also known as protein synthesis. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention.
Proceeds Purposes The funds will support an open-label Phase 1/2 trial that will evaluate daily oral administration of eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, in patients with advanced solid tumors. The Series B proceeds will fund multiple expansion arms for eFT508 in solid tumors and lymphoma, as well as advancing the company’s second program into the clinic.